Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Helus Pharma Inc. - Common Stock (NQ:HELP)

12.01 -0.28 (-2.28%)
Delayed Quote Updated: 2:41 PM EDT, Oct 1, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Helus Pharma Inc. - Common Stock

News headline image
Helus Pharma Eyes Q4 Phase III Data for HLP-003 in Major Depression ↗
Helus Pharma, formerly known as Cybin (NASDAQ:HELP), outlined its late-stage development plans for HLP-003 in adjunctive major depressive disorder (MDD) and discussed its broader pipeline of... 
Via MarketBeat
News headline image
Cybin Shareholders Weigh Helus Pharma Rebrand, Eight-Member Board ↗
Cybin (NASDAQ:HELP), doing business as Helus Pharma, held its Annual General and Special Meeting of Shareholders, where shareholders were asked to consider resolutions related to the company’s auditor,... 
Via MarketBeat
News headline image
Cybin Eyes Q4 Phase 3 Data for Depression Drug HLP003 ↗
Cybin (NASDAQ:HELP) executives outlined plans for its late-stage depression program, including an expected fourth-quarter Phase 3 data readout for HLP003, during H.C. Wainwright’s 28th Annual Global... 
Via MarketBeat
News headline image
Cybin Eyes Q4 Phase III Depression Readout as Psychedelic Pipeline Advances ↗
Helus Pharma Chief Executive Officer Michael Halstead said the company expects a pivotal Phase III readout for its HLP003 program in adjunctive major depressive disorder in the fourth quarter,... 
Via MarketBeat
News headline image
Cybin Conference: Helus CEO Eyes Q4 Phase III Depression Data for HLP003 ↗
Helus Pharma CEO Michael Halstead said the company is preparing for a potentially pivotal period as it expects top-line results in the fourth quarter from its first Phase III trial of HLP003 as an... 
Via MarketBeat
Topics Intellectual Property
News headline image
HELP Stock Crashes On Anxiety Trial Results, But Here’s Why Jefferies Sees Up To 200% Upside ↗
Jefferies highlighted the Phase 3 Approach trial for depression drug HLP003 as the next key catalyst for the stock. 
Via Stocktwits
News headline image
Dow Futures Hold Ground After 800-Point Selloff As Oil Surge Hits Wall Street: Why MRVL, USO, COST, HELP Are Trending After-Hours ↗
U.S. crude surged above $80 per barrel after a reported Iranian missile strike on an oil tanker. 
Via Stocktwits
Topics ETFs Stocks
News headline image
HELP Stock Tanks 22% Despite Strong Phase 2 Results For Anxiety Treatment: Retail Buys The Dip Ignoring Market’s Pessimism ↗
In the study, participants receiving a 20-milligram dose of HLP004 alongside standard-of-care treatment experienced an average drop of roughly 10.4 points on the Hamilton Anxiety Rating Scale after six... 
Via Stocktwits
News headline image
Magic Mushrooms, Hard Cash: Compass Pathways’ Trial Win, Fast Raise ↗
Via MarketBeat
News headline image
HELP Stock Rallies After Experimental Depression Drug Reduces Symptoms In Study: Retail Thinks Its ‘Time To Buy More’ ↗
The study showed statistically significant and clinically meaningful reductions in depressive symptoms at two weeks in participants treated with SPL026 compared with placebo, the company said. 
Via Stocktwits
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.